Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.60 price target on the stock.
Cara Therapeutics, Inc. (NASDAQ: CARA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Cara Therapeutics Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Cara Therapeutics Reports First Quarter 2024 Financial Results
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024